Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes.
The classification of these subtypes has evolved over the years. The most common and …

Interleukin-6 (IL-6) is a pleiotropic cytokine involved in immune regulation. It can activate
janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) signaling …

Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …

Background Immunotherapy in combination with chemotherapy has shown promising
efficacy across many different tumour types. We report the prespecified second interim …

Abstract mRNA vaccines have emerged as highly effective strategies in the prophylaxis and
treatment of diseases, thanks largely although not totally to their extraordinary performance …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–
negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

Breast cancer (BC) is a heterogeneous disease, encompassing a diverse spectrum of
tumours with varying morphological, biological, and clinical phenotypes. Although tumours …

Breast cancer is the most frequent cancer in women: in 2018, almost two million cases have
been diagnosed all over the world and it represents the principal cause of death from a …

Approximately 0.5 million people worldwide die from metastatic breast cancer (mBC) every
year. This manuscript provides an overview on the status of mBC in several regions of the …